TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06077890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Rehabilitation
Description: Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be able to access home-based rehabilitation strategies through dynamic content provided by SIMPLI.REHAB digital tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in this arm will undergo an in-person rehabilitation program coordinated by a Physiatrist and will be given home-based strategies in a printed paper brochure.
Study: NCT04918355

Intervention type: OTHER
Intervention: Clinical Decision Support (CDS) alerts
Description: CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.

Intervention type: OTHER
Intervention: Clinical Decision Support (CDS) alerts
Description: CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
Study: NCT05305300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
Description: receive one dose of PIKA COVID-19 vaccine (5 μg S protein/1mg PIKA, 10μg S protein/1mg PIKA and 20μg S protein/1mg PIKA) via IM administration on Days 0.
Study: NCT04800263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: SHR-1905 will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: SHR-1905 will be injected subcutaneously
Study: NCT04918355

Intervention type: OTHER
Intervention: Clinical Decision Support (CDS) alerts
Description: CDS alerts are pop-up boxes integrated into the EHR. Each alert provides patient specific information, a link to the PDMP, instructions on how to dismiss the alert, a link to study-specific educational website, and a comment field.
Study: NCT05292378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 600 ppm Carbon Dioxide
Description: 2.5 hour exposure to 600 ppm carbon dioxide
Study: NCT04800263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905
Description: SHR-1905 will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected subcutaneously
Study: NCT05292378

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 600 ppm Carbon Dioxide
Description: 2.5 hour exposure to 600 ppm carbon dioxide
Study: NCT05169229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin + Tobramycin
Description: 1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: As a placebo added to the allograft.
Study: NCT06547502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: single dose
Study: NCT04842981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Tocilizumab and Sarilumab are considered equal. Patients are assigned the treatment based on national and local guidelines. Intervention will be administered according to the approved posology.
Study: NCT05238883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200301
Description: Participants will be administered HFB200301 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200301
Description: Participants will be administered HFB200301 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200301
Description: Participants will be administered HFB200301 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HFB200301
Description: Participants will be administered HFB200301 as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will be administered tislelizumab as described in the experimental arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will be administered tislelizumab as described in the experimental arm.
Study: NCT05185414

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture and skin biopsy for RNA extraction
Description: * Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Venipuncture and skin biopsy for RNA extraction
Description: * Blood sampling (standard venipuncture)~* Skin biopsy (fibroblasts)
Study: NCT05797753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Capsule by oral administration
Study: NCT05262634

Intervention type: OTHER
Intervention: Data collection (laboratory and obstetric results)
Description: Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology

Intervention type: OTHER
Intervention: Data collection (laboratory and obstetric results)
Description: Maternal data: age, pregnancy, parity, singleton or multiple pregnancy, BMI, obstetric history data, and ethnicity.~Laboratory chemical results: hemoglobin (Hb), number of erythrocytes, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), number of hypochromic erythrocytes (HRC), erythrocyte distribution width (EBW), ferritin, C reactive protein (CRP).~Maternal pregnancy outcomes and complications: Hb before and after delivery, mode of delivery, placenta abruption, preeclampsia/eclampsia, gestational diabetes, gestational cholestasis, pregnancy-induced hypertension, bacteriuria or urinary tract infections, peripartum and postpartum hemorrhage, puerperal infections, uterine subinvolution.~Perinatal outcomes: gestational age, birth weight, intrauterine growth retardation, preterm birth, macrosomia, premature rupture of membranes, Apgar score, intrauterine fetal death, pH values, admission to neonatology
Study: NCT05005247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBS-NN/NN2
Description: GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2
Study: NCT05797753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin ethyl succinate
Description: Tablet by oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Capsule by oral administration
Study: NCT06470152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correction strategy in reference to our PI-dependent clustering of sagittal alignment
Description: For type I patients (PI \< 39.56°), the target LL = -0.13\*PI2+9.36\*PI-134.08; for type II patients (39.56° ≤ PI \< 49.16°), the target LL = 0.45\*PI+26.57; for type III patients (49.16° ≤ PI \< 58.31°), the target LL = -0.15\*PI2+17.09\*PI-420.57; for type IV patients (PI \> 58.31°), the target LL = 0.06\*PI2-7.55\*PI+289.77. Prediction intervals of 95% confidence is adopted as the target LL range.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Correction strategy in reference to the SAAS score
Description: This new score is composed of three sagittal parameters (PI-LL, PT and TPA). For these three parameters, points were assigned based on offset with age-adjusted targets 0 points if the parameter was within 10 years of the patient's age (Match). For each 20 years above the age-adjusted target, 1 point was added (e.g., + 1 point between + 10 and + 30, + 2 points between +30 and +50). Conversely, 1 point was subtracted for each 20 years below the age-adjusted target (e.g., -1 point between -10 and -30, -2 points between -30 and -50). SAAS was calculated by adding all 3 components, creating a discreet score that could have a negative value (under corrected) or positive value (over corrected). SAAS was sub-categorized into SAAS-Under if it was less than -1, SAAS-Match if it was between -1 and + 1 or SAAS-Over if it was greater than + 1.
Study: NCT05512780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: An exploratory study of a single-arm, open design~All subjects enrolled will receive the following treatment:~Dalpiciclib combined with Letrozole, 28 days as one cycle.
Study: NCT04858295

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail, voice), self-administered surveys, and secure data capture for research purposes. Way to Health has been used successfully in prior behavior intervention studies.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth app
Description: Omron Connect app available on a participant's smartphone connects to the participant's home Omron blood pressure monitor via bluetooth technology. The Omron Connect app, which stores the blood pressure readings and provides reminders to the participant via push notifications also communicates with the Way to Health research platform via Internet connection.
Study: NCT00311545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 328
Description: Anti-IL-6 chimeric monoclonal antibody
Study: NCT04702594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy session via tools validated by MUSIC CARE
Description: Use of the MUSICARE tool, a digital space allowing access to different validated methods of music therapy. Music listening times are offered to patients with cognitive impairment with psycho-behavioral symptoms. The sessions are individual or group performed by a psychomotor therapist in UHR and volunteer caregivers trained in SRH. The sessions last on average 20-30min.
Study: NCT06144723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20105
Description: Administered intravenously every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20105
Description: Administered intravenously every 21 days.
Study: NCT06585462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 513
Description: AMG 513 will be administered by SC or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 513
Description: AMG 513 will be administered by SC or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by SC or IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered by SC or IV injection.
Study: NCT06424223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal Ridge augmentation
Description: A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa.~Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures.
Study: NCT05627557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: MMF will be administered as per schedule specified in the respective arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants taking prednisone or equivalent at randomization will follow a guided tapering schedule to reach the goal of 0mg/day by Weeks 4-6 (and no later than Week 8 following randomization and continue without prednisone through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 80 mg (or 1.5 mg/kg if \</=45 kg) IV will be administered as premedication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/ Paracetamol
Description: Acetaminophen 15 mg/kg (maximum dose 1000 mg) will be administered PO as premedication prior to infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine Hydrochloride
Description: Diphenhydramine HCl 0.5-1 mg/kg (maximum dose 50 mg) will be administered PO or IV as premedication prior to infusions.
Study: NCT06420297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin nasal spray 3.2 mg three times daily (TID)
Study: NCT06377540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive 200 mg Pembrolizumab on Day -28 and Day -6 by IV infusion.~Pembrolizumab 200 mg IV will resume at day 30+ after ASCT every 3 weeks for 1 year.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Description: On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Patient will receive a single dose of BCNU on day -6, dose of 300 mg/m2 by IV infusion.
Study: NCT05974631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Prolonged Exposure protocol
Description: DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure therapy
Description: Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Suicide risk management
Description: Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.
Study: NCT06377540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be given at dose 100 mg/m2 BID intravenously on days -5, - 4, -3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given at dose 100 mg/m2 BID intravenously on days -5, -4, - 3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given at dose of 140 mg/m2 intravenously on day -1 in a single 20 minute infusion; dose will be based on actual body weight but capped at 3.6 mg/kg as part of BEAM conditioning.
Study: NCT05333835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR17031 injection
Description: HR17031 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INS068 injection
Description: INS068 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR20004 injection
Description: SHR20004 injection
Study: NCT06298747

Intervention type: OTHER
Intervention: Selective cervical nerve root pulsed radiofrequency
Description: A 5-12 MHz linear US probe was used during the procedure. C7 has a more prominent posterior tubercle and a rudimentary anterior tubercle. C5 and C6 have more prominent and smooth anterior and posterior tubercles, respectively. After visualizing the hypoechoic nerve root between the tubercles of the transverse process, the surrounding vascular structures were identified and RF canula is used. After approaching the hypoechoic nerve root, after sensory and motor stimulation, PRF was applied to each nerve root.
Study: NCT06139835

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tartarase
Description: Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tartarase
Description: Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tartarase
Description: Brushing with a formulation containing DNase 1 and chymotrypsin to assess its efficacy at removing accumulated calculus
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: ALK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: MEK1, MEK2
Study: NCT06463314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI Multiplex HIV/Syphilis Antibody Test
Description: The INSTI® Multiplex HIV-1/HIV-2 Syphilis Antibody Test (bioLytical Laboratories Inc., Richmond, BC), \[INSTI Multiplex Test\] is a single use, rapid, flow-through in vitro qualitative immunoassay for the detection of antibodies to HIV Type 1 and 2 and Treponema pallidum (Syphilis) in human fingerstick blood and serum. The test is intended to screen for HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and Syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than one minute. This test is licensed by Health Canada.
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Hedgehog

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Pertuzumab
Description: HER2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: NTRK/ ROS1, ALK
Study: NCT04853368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-576
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galicaftor
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navocaftor
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-119
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-119
Description: Oral capsules
Study: NCT04785794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sing2016 M2SR H3N2 influenza vaccine
Description: This group will receive a dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally on Day 1 followed by IIV at least 28 days later.
Study: NCT05597189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Botanical extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product
Description: Botanical extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Product with identical characteristics to the experimental product.
Study: NCT05159245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PD-L1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: BRAF V600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: KIT/BRAF, RET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: AR